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Conclusions: We found that dose to the intestinal cavity 
(V32Gy and V46Gy) was associated with acute diarrhea and 
chemotherapy treatment compliance in patients treated with 
IMRT for primary rectal cancer. The results are not in direct 
agreement with results from patient cohorts treated with 3D-
CRT, where V15Gy has consistently been reported as an 
optimal dose cut-off. 
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Purpose/Objective: Opinion in the literature is divided as to 
whether the LQ model of cell kill, and consequently TCP 
models based on it, are applicable for the relatively high 
dose per fraction delivered during SABR treatments of NSCLC. 
This work aimed to establish whether LQ-based TCP 
modelling can adequately describe observed local control in 
NSCLC radiotherapy for both 3D-CRT and SABR deliveries, 
through fitting model parameters to reported outcomes for 
both techniques. 
Materials and Methods: Two patient cohorts, each 
comprising approximately 25 clinical PTV DVHs, were 
constructed from retrospective clinical data for mixed-stage 
3D-CRT and stage I SABR treatments. Cohorts differed in GTV 
sizes (averaging 106 cm3 for 3D-CRT and 15 cm3 for SABR) and 
dose variation due to the lower isodose level (67 to 80% of 
isocentre dose) covering the PTV for SABR. An LQ-based TCP 
model was used to predict local control for individual PTV 
DVHs, which were then averaged over each cohort to 
estimate local control for that population. Fixed parameters 
were clonogen density within the GTV (1e7 cm-3), alpha-beta 
ratio (10 Gy), time to the onset of accelerated repopulation, 
Tk (21 days) and doubling time, Td (3.7 days). Free 
parameters fitted to published outcome data were mean 
radiosensitivity, α, and standard deviation σα. Parameters 
were fitted to reported local control at 2 years for a range of 
dose/fractionation schedules using maximum likelihood 
estimation. Best fit parameters were derived for combined 
3D-CRT and SABR outcome data and for each technique 
separately. Uncertainty estimates on derived parameter 
values were derived from likelihood profiles to assess the 
significance of parameter set differences. 
Results: Best-fit TCP model parameters (and 95% confidence 
intervals) for combined 3D-CRT and SABR cohorts were α = 
0.293 (0.286 to 0.302) Gy-1 and σα = 0.051 (0.042 to 0.067). 
Best-fit parameters resulting from separate fitting to only 3D-
CRT data fell within the 95% confidence limits of these 
values. For SABR-only fitting, α (only) fell outside this 
confidence interval; α = 0.313, σα = 0.06, however the 95% 
confidence interval on SABR-derived α (0.292 to 0.342) 
encompassed the fit to combined data. Resulting local 
control estimates are compared with the literature in the 
figure below, along with the predictions for separate model 
fitting to 3D-CRT and to SABR data. Repopulation-corrected 
equivalent 2Gy dose (EQD2) to the isocentre is used as the 
metric, indicating a smooth transition from 3D-CRT to SABR 
techniques. 
 
Conclusions: An LQ-based TCP model was found to 
adequately reproduce reported 2-year local control for both 
3D-CRT and SABR NSCLC techniques. Further, a common 
parameter set (α, σα) was found to be consistent with data 
for both techniques, despite the large dose and GTV size 
differences between patient cohorts. No significant 
advantage was found in fitting parameters to each technique 
separately.  
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